Literature DB >> 8697458

Primary CNS demyelinating diseases in childhood: multiple sclerosis.

P Iannetti1, M G Marciani, A Spalice, F Spanedda, U Raucci, G Trasimeni, G F Gualdi, G Bernardi.   

Abstract

We report on five children (three female and two male, age span 11-16 years) with laboratory-supported definite multiple sclerosis or clinically definite multiple sclerosis, diagnosed on the basis of Poser and Paty criteria. All patients were subjected to serial clinical examinations, magnetic resonance investigations, CSF biochemical and immunological studies, and neurophysiological and neuropsychological assessments. Four of the five examined subjects underwent steroid treatment. Over a period of 3 years relapses have been observed in three of them. The first symptoms and signs of multiple sclerosis may be subtle and misleading; careful assessment of them may be crucial for an early diagnosis of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697458     DOI: 10.1007/bf00266819

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  26 in total

Review 1.  The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review.

Authors:  D S Goodin
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

2.  Diagnosing multiple sclerosis in childhood.

Authors:  H B van Lieshout; B G van Engelen; E A Sanders; W O Renier
Journal:  Acta Neurol Scand       Date:  1993-11       Impact factor: 3.209

Review 3.  Magnetic resonance in multiple sclerosis.

Authors:  D W Paty
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-04

4.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

5.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

Review 6.  Anatomical and functional correlates of cognitive deficit in multiple sclerosis.

Authors:  C Pozzilli; C Gasperini; A Anzini; M G Grasso; G Ristori; C Fieschi
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

7.  Cladribine in treatment of chronic progressive multiple sclerosis.

Authors:  J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff; E Beutler
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

8.  Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children.

Authors:  R Riikonen; M Donner; H Erkkilä
Journal:  Dev Med Child Neurol       Date:  1988-06       Impact factor: 5.449

9.  Recovery after optic neuritis in childhood.

Authors:  A Kriss; D A Francis; F Cuendet; A M Halliday; D S Taylor; J Wilson; J Keast-Butler; J R Batchelor; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

10.  Multiple sclerosis in childhood: report of 15 cases.

Authors:  F Hanefeld; H J Bauer; H J Christen; B Kruse; H Bruhn; J Frahm
Journal:  Brain Dev       Date:  1991-11       Impact factor: 1.961

View more
  2 in total

1.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 2.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.